Does SELPERCATINIB Cause Malignant neoplasm progression? 106 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 106 reports of Malignant neoplasm progression have been filed in association with SELPERCATINIB (RETEVMO). This represents 9.8% of all adverse event reports for SELPERCATINIB.
106
Reports of Malignant neoplasm progression with SELPERCATINIB
9.8%
of all SELPERCATINIB reports
31
Deaths
32
Hospitalizations
How Dangerous Is Malignant neoplasm progression From SELPERCATINIB?
Of the 106 reports, 31 (29.2%) resulted in death, 32 (30.2%) required hospitalization, and 4 (3.8%) were considered life-threatening.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for SELPERCATINIB. However, 106 reports have been filed with the FAERS database.
What Other Side Effects Does SELPERCATINIB Cause?
Death (90)
Hypertension (58)
Hypersensitivity (55)
Diarrhoea (54)
Fatigue (51)
Rash (49)
Hepatic function abnormal (42)
Alanine aminotransferase increased (38)
Pyrexia (38)
Aspartate aminotransferase increased (37)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which SELPERCATINIB Alternatives Have Lower Malignant neoplasm progression Risk?
SELPERCATINIB vs SELUMETINIB
SELPERCATINIB vs SEMAGLUTIDE
SELPERCATINIB vs SEMUSTINE
SELPERCATINIB vs SENNA LEAF
SELPERCATINIB vs SENNA LEAF\SENNOSIDES\SENNOSIDES A AND B